220461-68-7

Basic information

• Product Name: 2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid
• Synonyms: 2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid;2-chloro-4-(3-methylpyrazol-1-yl)benzoic acid
• CAS NO: 220461-68-7
• Molecular Formula: C₁₁H₉ClN₂O₂
• Molecular Weight: 236.65436
• Mol File: 220461-68-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 186～189℃
• Boiling Point: 397℃
• Flash Point: 194℃
• Appearance: /
• Density: 1.38
• CAS DataBase Reference: 2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid(220461-68-7)
• EPA Substance Registry System: 2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid(220461-68-7)

Safety Data

• Hazardous Substances Data: 220461-68-7(Hazardous Substances Data)

Usage

General Description

2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid is a chemical compound with a molecular formula C10H8ClN3O2. It is a derivative of benzoic acid and contains a chlorine and a pyrazole ring in its structure. 2-Chloro-4-(3-Methyl-1H-pyrazol-1-yl)benzoic acid is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It can also be used as a building block in the production of various organic compounds. The presence of the chloro and pyrazole groups in this chemical make it a versatile and important building block in the production of diverse bioactive compounds. Its synthesis and application is of interest to medicinal and pharmaceutical industries.

Upstream product

• 21900-54-9 2-chloro-4-fluorobenzoyl chloride 
• 220461-67-6 2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzamide 
• 85953-29-3 methyl 2-chloro-4-fluorobenzoate 
• 220462-02-2 2-chloro-4-(3-methylpyrazol-1-yl)benzoic acid methyl ester 

Downstream Products

• 233755-70-9 2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl chloride 
• 220460-92-4 VNA-932 
• 220602-55-1 [2-chloro-4-(3-methyl-1H-pyrazol-1-yl)-phenyl]-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 
• 220461-67-6 2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzamide 
• 1143023-20-4 2-chloro-N-[(6-{[3-(4-methylpiperazin-1-yl)propyl]sulfonyl}-1,3-benzothiazol-2-yl)carbamoyl]-4-(3-methyl-1H-pyrazol-1-yl)benzamide 
• 1209963-38-1 5-[2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-1-methyl-1,4,5,10-tetrahydro pyrazolo[3,4-b][1,5]benzodiazepine 

Relevant articles and documents

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.

Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists

A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V2 receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V2 binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V1a receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V2 receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats.

Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V2 receptor agonists

The present work describes the discovery of novel series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin (AVP) V2 receptor agonists. By replacing the amide juncture in YM-35278 with a direct ring connection gave compound 10a, which acts as a V2 receptor agonist. These studies provided the potent, orally active non-peptidic V2 receptor agonists 10a and 10j.